MOTS-c longevity: what aging research shows, and what it does not

MOTS-c longevity research looks at a mitochondrial peptide whose blood levels appear to fall with age, and which improved physical capacity when given to old mice. That is a healthspan signal in animals, not proof of longer life. No study has tested whether MOTS-c extends human lifespan, and MOTS-c is not FDA-approved.

Longevity is where MOTS-c gets the most hype. You will see it called an anti-aging peptide or a youth signal from your mitochondria. Some of that language comes from real science. Much of it skips the part where the science was done in mice.

This guide walks through the MOTS-c aging research in order: what happens to levels as we age, what aged-mouse studies found, how the peptide signals stress, and what nobody knows yet about human lifespan. Also searched as: mots-c anti aging, mots-c aging research, mitochondrial peptide longevity, mots c, motsc and peptide mots-c.

Why MOTS-c longevity became a research question

Mitochondria are the energy centres of your cells, and their decline is one of the recognised features of aging. They also carry their own small genome. In 2015, researchers found that a short stretch of that mitochondrial DNA codes for a 16-amino-acid signal, the MOTS-c peptide, which targets skeletal muscle and activates AMPK, the cell's energy sensor (Lee et al., 2015).

The same study showed MOTS-c prevented age-dependent insulin resistance in mice. That single finding opened the MOTS-c longevity question: if mitochondria send signals that help regulate metabolism, could those signals fade with age, and could replacing them help? For the wider family of these peptides, see our guide to mitochondrial-derived peptides.

Do MOTS-c levels decline with age?

Partly, and it depends where you measure. A study of healthy men in three age groups (18 to 30, 45 to 55 and 70 to 81) found circulating MOTS-c was lower with age. Inside skeletal muscle, though, older and middle-aged men had higher MOTS-c than young men (D'Souza et al., 2020). The authors linked the muscle finding to a shift toward slow-twitch muscle fibres with age.

A 2022 review summarised the field as showing plasma levels that decline with age (Mohtashami et al., 2022). In mice, MOTS-c in pancreatic islet cells also fell with aging (Kong et al., 2025).

So the honest version of the MOTS-c aging research is this: blood levels seem to drop, tissue levels may not, and nobody has shown that a lower level causes aging rather than simply tracking it.

MOTS-c longevity in aged mice: the key study

The most cited MOTS-c longevity paper is a 2021 study in Nature Communications (Reynolds et al., 2021). Its main findings, from the published abstract:

• Physical performance: MOTS-c improved physical performance in young (2 months), middle-aged (12 months) and old (22 months) mice.
• Late-life treatment: intermittent MOTS-c started at 23.5 months, given three times a week, increased physical capacity and healthspan in mice.
• Gene regulation: MOTS-c affected nuclear genes linked to metabolism and protein maintenance in muscle.
• Human link: in people, exercise raised the body's own MOTS-c in muscle and blood.

Two cautions matter. First, healthspan (time spent in good health) is not lifespan. The abstract does not report that MOTS-c made mice live longer. Second, a 23.5-month-old mouse is a useful model, not a stand-in for a 75-year-old person.

The exercise link is one reason MOTS-c is described as an exercise mimetic, covered in our exercise mimetic explainer. For tested athletes, USADA notes that MOTS-c is prohibited at all times under WADA category S4, hormone and metabolic modulators, as an AMPK activator.

Mitochondrial stress signalling: how MOTS-c might matter for aging

The mechanism behind mitochondrial peptide longevity ideas is about communication. Normally, the nucleus tells mitochondria what to do. MOTS-c runs the other way.

In cells under metabolic stress, such as glucose restriction, MOTS-c moved into the nucleus in an AMPK-dependent way. There it regulated a broad set of genes, including those with antioxidant response elements, and interacted with the stress-response factor NRF2 (Kim et al., 2018).

Why does that matter for aging? Cells that cope well with stress tend to age better, at least in lab models. A 2025 study supports the idea in one tissue: MOTS-c reduced senescence, the state where aging cells stop dividing but keep sending inflammatory signals, in aged mouse pancreatic islets (Kong et al., 2025).

These are mechanisms, not outcomes. They explain why scientists are interested, not what MOTS-c does in an aging person. If you want the broader biology, our mitochondrial biogenesis guide explains how cells build new mitochondria.

The genetics angle: a variant linked to long life and to diabetes

The most intriguing human clue for MOTS-c longevity is genetic. An East Asian variant, m.1382A>C, changes one amino acid in MOTS-c (known as K14Q). In 2015, researchers proposed that this variant might be among the reasons for exceptional longevity in Japan, and framed it as a question (Fuku et al., 2015).

Later work complicated the story. In more than 27,000 people across three cohorts, men carrying the same variant had a higher prevalence of type 2 diabetes, especially if they were physically inactive. The variant form of MOTS-c also had weaker insulin-sensitising activity (Zempo et al., 2021). Another study tied it to more fast-twitch muscle fibre and sprint and power performance (Kumagai et al., 2022).

Genetics like this cannot tell you what an injected peptide will do. It does show MOTS-c biology varies between people.

MOTS-c longevity: what we know vs what we don't

What is not known about MOTS-c and human lifespan

This is the section most MOTS-c anti aging claims leave out:

1. Lifespan in humans. No study has tested it. None is likely soon, because lifespan trials take decades.
2. Healthspan in humans. No controlled trial has given MOTS-c to older adults and measured strength, mobility or disease.
3. Dose. There is no established human dose. Mouse doses do not translate directly, and online charts are not evidence-based.
4. Long-term safety. Human safety data are very limited, and nothing is known about years of use.
5. Cause or marker. Lower blood MOTS-c in older people may be a consequence of aging, not a driver.

Any promise that MOTS-c will make you younger, add years or reverse aging goes beyond the research. The accurate phrase is "studied in aging research," and it is why the MOTS-c protocol at telos rx is framed around provider review, not anti-aging promises.

Safety and regulatory status

MOTS-c is not FDA-approved for any use. Reported or theorised side effects include injection-site reactions, fatigue, headache, nausea and changes in blood sugar, which matters for anyone on diabetes medication. It is not for use in pregnancy or breastfeeding. Our MOTS-c side effects guide has more.

In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding MOTS-c to the list of bulk substances for compounding, against the recommendation in FDA's briefing documents. The vote is advisory and non-binding. On October 28, 2026, HHS announced an interim enforcement discretion policy: it does not intend to take action against state-licensed pharmacies that compound single-ingredient MOTS-c for subcutaneous or intramuscular injection with a valid prescription, under strict sourcing, testing and reporting conditions. It is temporary while FDA rulemaking continues, it is not FDA approval, and HHS can revisit it. Read our PCAC vote explainer for the detail. Grey-market vials sold as "research use only" have unverified identity, strength and sterility.

How telos rx approaches MOTS-c

MOTS-c at telos rx follows an online, asynchronous prescription route:

1. Online intake. You share your health history, medications and goals.
2. Provider review. A US-licensed provider reviews it without a scheduled appointment. A prescription is required, subject to medical approval by a licensed provider, and approval is not guaranteed.
3. Licensed pharmacy. If approved, a licensed US pharmacy compounds MOTS-c as a subcutaneous injection, at a dose and schedule your provider sets.
4. Ongoing care. You can message the care team, and plans can be cancelled from the portal.

telos rx does not offer oral or tablet MOTS-c. See the MOTS-c page for how the program works. For an evidence-graded look at every claim, read MOTS-c benefits, graded by evidence. If you are comparing cellular-energy options, see MOTS-c vs NAD+ or our NAD+ injection guide.

Frequently asked questions about MOTS-c longevity

Does MOTS-c extend lifespan?

There is no evidence that MOTS-c extends human lifespan. MOTS-c longevity research in mice reports better physical capacity and healthspan markers in old animals, which is not the same as living longer, and no human lifespan study exists.

What does MOTS-c longevity research actually study?

MOTS-c longevity research looks at how the body's own MOTS-c levels change with age, what happens when old mice are given MOTS-c, and how the peptide signals mitochondrial stress to the cell nucleus.

Do MOTS-c levels decline with age?

One study of healthy men found lower circulating MOTS-c in older age groups, while levels inside muscle were higher in older men. Reviews describe plasma MOTS-c as declining with age, but human data are still limited.

Is MOTS-c an anti aging peptide?

MOTS-c is studied in aging research, but calling it an anti-aging treatment goes beyond the evidence. MOTS-c is not FDA-approved, and no controlled human trial has shown it slows aging.

Is mots c the same as the MOTS-c peptide?

Yes. mots c, motsc, mots-c peptide and peptide mots-c all refer to the same 16-amino-acid peptide encoded in mitochondrial DNA.

Can athletes use MOTS-c?

Tested athletes should not. According to USADA, MOTS-c is prohibited at all times under WADA category S4, hormone and metabolic modulators, as an AMPK activator.

How can I talk to a provider about MOTS-c?

At telos rx, you complete an online intake that a US-licensed provider reviews asynchronously. If appropriate, a licensed US pharmacy compounds MOTS-c as a subcutaneous injection. Every prescription is subject to medical approval by a licensed provider, and approval is not guaranteed.

This article is for general education and is not medical advice. MOTS-c is not FDA-approved for any use, and compounded MOTS-c has not been evaluated by the FDA for safety, effectiveness or quality. All prescriptions are subject to medical approval by a licensed provider; approval is not guaranteed. Individual experiences vary. telos rx is an online-first, asynchronous telehealth service, and medications are compounded by a licensed US pharmacy. MOTS-c is prohibited in sport under WADA category S4.